Boston Scientific Corporation $BSX Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

Key Points

• British Columbia Investment Management Corp reduced its stake in Boston Scientific by 26%, leaving it with 281,860 shares valued at approximately $28.4 million.
• Boston Scientific reported $5.06 billion in revenue for its most recent quarter, exceeding analysts' expectations of $4.89 billion, with a year-over-year revenue increase of 22.8%.
• Research analysts have set a consensus rating of "Buy" on Boston Scientific, with target prices ranging from $117.00 to $125.00.

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 26.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 281,860 shares of the medical equipment provider's stock after selling 99,203 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Boston Scientific were worth $28,434,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. NS Partners Ltd lifted its stake in Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Bank Pictet & Cie Europe AG increased its holdings in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Boston Scientific by 18.8% in the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after purchasing an additional 6,264 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in Boston Scientific during the first quarter worth approximately $8,234,000. Finally, Blue Trust Inc. boosted its stake in Boston Scientific by 13.0% during the first quarter. Blue Trust Inc. now owns 5,000 shares of the medical equipment provider's stock worth $504,000 after buying an additional 575 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BSX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Oppenheimer upped their price objective on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a report on Thursday, July 24th. Leerink Partners began coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Erste Group Bank upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Finally, Barclays increased their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and an average target price of $117.50.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 345,029 shares of company stock worth $35,976,603. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 0.4%

Shares of BSX traded down $0.45 during mid-day trading on Wednesday, hitting $105.94. 5,706,463 shares of the company's stock were exchanged, compared to its average volume of 7,526,416. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a fifty-two week low of $79.03 and a fifty-two week high of $108.94. The company has a market cap of $156.98 billion, a price-to-earnings ratio of 63.06, a P/E/G ratio of 2.53 and a beta of 0.66. The stock's 50-day moving average is $104.27 and its 200-day moving average is $102.15.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.